Synthetic fragments of the NS1 protein of the tick-borne encephalitis virus exhibiting a protective effect

Volkova, T. D.; Короев, Д. О.; Titova, M. A.; Oboznaya, M. B.; Filatova, M. P.; Vorovich, M. F.; Ozherelkov, S V; Timofeev, A.; Volpina, O. M.

doi:10.1134/s1068162007020021

Cited by 3 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies showed that NS1 immunization or passive transfer of anti-NS1 antibodies afforded protection against infections with flaviviruses, such as DENV, YFV and WNV in animal models [ 117 , 118 , 119 , 120 , 121 , 122 , 123 ]. These findings have been confirmed for the TBEV NS1 protein [ 97 , 101 , 105 , 106 , 107 , 108 , 124 ]. Mouse studies showed that immunization with a synthetic peptide corresponding to the structurally conserved α-helix (aa37–55) of NS1 [ 108 ] or with various synthetic fragments of NS1 [ 101 ] induced partly protective immunity against lethal challenge infection with TBEV.…”

Section: Immune Response To Tbev Infection and Vaccinationmentioning

confidence: 62%

“…These findings have been confirmed for the TBEV NS1 protein [ 97 , 101 , 105 , 106 , 107 , 108 , 124 ]. Mouse studies showed that immunization with a synthetic peptide corresponding to the structurally conserved α-helix (aa37–55) of NS1 [ 108 ] or with various synthetic fragments of NS1 [ 101 ] induced partly protective immunity against lethal challenge infection with TBEV. In addition, significantly prolonged survival of TBEV-infected mice was observed after hyperimmunization with a whole recombinant TBEV NS1 protein, although all mice succumbed to infection [ 97 ].…”

Section: Immune Response To Tbev Infection and Vaccinationmentioning

confidence: 62%

“…Additionally, vaccination induced significant EDI- and EDII-specific CD4 + T cell responses, whereas CD4 + T cell responses against peptides from the stem region of E were predominantly observed in TBE patients [ 99 ]. Besides the identified CD4 + T cell epitopes in the structural proteins, several predicted T helper cell epitopes were located in the NS1 protein of TBEV [ 101 ]. In general, individual variation in CD4 + T cell peptide specificity as well as cytokine profile was seen in TBEV naturally infected and vaccinated persons [ 98 , 99 ].…”

Section: Immune Response To Tbev Infection and Vaccinationmentioning

confidence: 99%

“…Besides VN antibodies against the E protein, anti-NS1 antibodies were detectable in sera of TBE patients [ 94 , 95 , 96 , 97 ]. Mouse studies showed that these antibodies afforded partial protection from TBEV infection [ 97 , 101 , 108 ]. Therefore, the NS1 protein may be considered a promising additional vaccine target in future TBEV vaccines.…”

Section: Novel Approaches and Tbev Target Antigens For The Developmentioning

confidence: 99%

“…TBEV CD4 + T cell epitopes ( Table 2 ) were identified within the E and C proteins [ 98 , 99 ]. Predictions suggested the presence of epitopes in the TBEV NS1 protein [ 101 ]. Comparable immunodominant epitopes in E and C were identified for ZIKV, DENV, YFV and JEV [ 155 , 156 ].…”

Section: Novel Approaches and Tbev Target Antigens For The Developmentioning

confidence: 99%

See 4 more Smart Citations

Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise

et al. 2020

View full text Add to dashboard Cite

Tick-borne encephalitis virus (TBEV), a member of the family Flaviviridae, is one of the most important tick-transmitted viruses in Europe and Asia. Being a neurotropic virus, TBEV causes infection of the central nervous system, leading to various (permanent) neurological disorders summarized as tick-borne encephalitis (TBE). The incidence of TBE cases has increased due to the expansion of TBEV and its vectors. Since antiviral treatment is lacking, vaccination against TBEV is the most important protective measure. However, vaccination coverage is relatively low and immunogenicity of the currently available vaccines is limited, which may account for the vaccine failures that are observed. Understanding the TBEV-specific correlates of protection is of pivotal importance for developing novel and improved TBEV vaccines. For affording robust protection against infection and development of TBE, vaccines should induce both humoral and cellular immunity. In this review, the adaptive immunity induced upon TBEV infection and vaccination as well as novel approaches to produce improved TBEV vaccines are discussed.

show abstract

Section: Immune Response To Tbev Infection and Vaccinationmentioning

confidence: 62%

Section: Immune Response To Tbev Infection and Vaccinationmentioning

confidence: 62%

Section: Immune Response To Tbev Infection and Vaccinationmentioning

confidence: 99%

Section: Novel Approaches and Tbev Target Antigens For The Developmentioning

confidence: 99%

Section: Novel Approaches and Tbev Target Antigens For The Developmentioning

confidence: 99%

See 3 more Smart Citations

Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise

et al. 2020

View full text Add to dashboard Cite

show abstract

Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice

et al. 2023

View full text Add to dashboard Cite

IntroductionTick-borne encephalitis virus (TBEV) is one of the most relevant tick-transmitted neurotropic arboviruses in Europe and Asia and the causative agent of tick-borne encephalitis (TBE). Annually more than 10,000 TBE cases are reported despite having vaccines available. In Europe, the vaccines FSME-IMMUN® and Encepur® based on formaldehyde-inactivated whole viruses are licensed. However, demanding vaccination schedules contribute to sub-optimal vaccination uptake and breakthrough infections have been reported repeatedly. Due to its immunogenic properties as well as its role in viral replication and disease pathogenesis, the non-structural protein 1 (NS1) of flaviviruses has become of interest for non-virion based flavivirus vaccine candidates in recent years.MethodsTherefore, immunogenicity and protective efficacy of TBEV NS1 expressed by neuraminidase (NA)-deficient Influenza A virus (IAV) or Modified Vaccinia virus Ankara (MVA) vectors were investigated in this study.ResultsWith these recombinant viral vectors TBEV NS1-specific antibody and T cell responses were induced. Upon heterologous prime/boost regimens partial protection against lethal TBEV challenge infection was afforded in mice.DiscussionThis supports the inclusion of NS1 as a vaccine component in next generation TBEV vaccines.

show abstract

The importance of the role of T-cell immunity in the development of modern tick-borne encephalitis vaccines

Tigeeva,

Nizolenko,

Karpenko

2024

Journal of microbiology, epidemiology and immunobiology

View full text Add to dashboard Cite

The tick-borne encephalitis (TBE) virus is highly pathogenic and can affect the central nervous system, leading to severe chronic effects or death. The only effective measure to combat TBE is vaccine prophylaxis. Vaccines that are currently used for mass immunization are based on inactivated TBE virus, they provide a protective immune response, but such vaccines require multiple administrations. A possible reason for short-term immunity is an incomplete functional T-cell response to these types of vaccines. The aim of this review is to analyze the literature on the role of the T-cell immune response in protecting the body from tick-borne encephalitis, its importance for vaccine development, and to consider approaches to the development of new TBE vaccines based on different platforms. When preparing the review, we analyzed the literature presented in scientific databases — PubMed, Scopus, Elsevier, Google Scholar as of April 2024. The following keywords were used for the search: vaccine, tick-borne encephalitis virus, T-cell immune response, flaviviruses. A several publications have demonstrated that T-cell responses following natural infection with TBE virus and after vaccination with inactivated virus are different. During viral infection, both Th1- and Th2-type CD4+ T cells and CD8+ T cells are activated and play an important role in the elimination of viral infection. After vaccination, the only Th2-type CD4+ T-cell response predominates, which may be the reason for the short-lived immune response. To date, a number of different types of experimental TBE vaccines are being studied, such as live-attenuated vaccines, viral vector vaccines, subunit vaccines, virus-like particles, DNA and mRNA vaccines, and polyepitope immunogens. In our opinion, the most promising in terms of T-cell response activation are vaccines based on T-cell polyepitope immunogens delivered in the form of DNA or mRNA.

show abstract

Synthetic fragments of the NS1 protein of the tick-borne encephalitis virus exhibiting a protective effect

Cited by 3 publications

References 13 publications

Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise

Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise

Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice

The importance of the role of T-cell immunity in the development of modern tick-borne encephalitis vaccines

Contact Info

Product

Resources

About